See What Leading Cardiovascular Programs Are Doing
The Solution 
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
The Solution
Improving Outcomes
This leading-edge solution delivers actionable insights through intuitive digital-health platforms, proprietary A.I. powered analytics and deep clinical expertise to help leading systems elevate the standard of patient care.
Cardiocare resources
Learn how the CardioCare platform drives growth for progressive heart programs. Click here.
Learn how the CardioCare platform surfaces the right patients and streamlines referral-to-treatment workflows. Click here.
Learn about the experience of a large heart program using the CardioCare platform. Click here.
Learn about the experience of a large heart program using the CardioCare platform. Click here.
Learn about the experience of a mid-sized heart program using the CardioCare platform. Click here.
Learn about the experience of a mid-sized heart program using the CardioCare platform. Click here.
Learn about the experience of St. Luke’s with the CardioCare platform. Click here.
Learn about the experience of Altru with the CardioCare platform. Click here.
Partner Sites
Working with Top Cardiovascular Programs Across the U.S.
Don't just take our word for it. Talk to our team today to learn more about partnerships.
MORE CONTENT
Subscribe to Our YouTube Channel
Testimonials
Leading hospitals partner with egnite’s CardioCare platform to reduce variability in care and improve guideline-directed therapy for patients with cardiovascular disease.
Gagnon Cardiovascular Institute, Morristown Medical Center
Resources
egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to improve cardiovascular patient care nationwide.
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.